ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1869

Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients

Hitoshi Uga1, Takahiro Okazawa1, Yoshiaki Miyamoto1, Takehiro Hasegawa1, Jun Saegusa2, Goh Tsuji3, Sho Sendo4, Akio Morinobu5, Shunichi Kumagai6,7 and Hirokazu Kurata1, 1Sysmex Corporation, Kobe, Japan, 2Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, 3Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, 4Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, 5Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Center of rheumatic diseases, Shinko hospital, Kobe, Japan, 7Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, Biomarkers, cytokines, Diagnosis and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study was designed to evaluate serum levels of cytokines/chemokines and to establish a new discriminating system of ACPA-negative RA patients from non-RA arthritic patients and healthy controls.

Methods:

A total of 174 RA patients (mean DAS28-CRP = 2.67; 104 ACPA-positive and 70 ACPA-negative patients) diagnosed according to the ACR/EULAR 2010 classification criteria for RA, 33 non-RA arthritic (NRA) patients including seronegative spondyloarthropathy (SNSA), and 76 sex-matched healthy controls (HC) were included. By using a chemi-luminescence immunoassay, twenty-eight cytokines/chemokines, including IFN-g, TNF-a, IL-1b, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-17F, IL-23, CCL20, CXCL13, TGF-b1, were measured in the sera of the above populations. Results were analyzed by Mann-Whitney U-test. Discriminant analysis was performed using multiple logistic regression analysis.

Results:

Our study revealed that (1) several cytokines/ chemokines, including IFN-g, TNF-a and novel cytokines were upregulated in RA patients as compared with in healthy controls. (2) Multiple logistic regression analysis revealed that the combinations of three to five cytokines/chemokines could clearly discriminate not only ACPA-positive but also ACPA-negative RA patients from NRA patients as well as RA patients from HC (Figure 1);ACPA-negative RA: 70, NRA: 33, HC:76).

Conclusion:

Our study using a chemi-luminescence immunoassay led to the identification of cytokine/chemokine profiles useful in the differential diagnosis of ACPA-negative RA from non-RA arthritis.


Disclosure:

H. Uga,

Sysmex Corporation,

3;

T. Okazawa,

Sysmex Corporation,

3;

Y. Miyamoto,

Sysmex Corporation,

3;

T. Hasegawa,

Sysmex Corporation,

3;

J. Saegusa,
None;

G. Tsuji,
None;

S. Sendo,
None;

A. Morinobu,
None;

S. Kumagai,
None;

H. Kurata,

Sysmex Corporation,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-cytokinechemokine-profiles-are-useful-for-evaluating-pathological-conditions-of-rheumatoid-arthritis-and-diagnosing-anti-ccp-antibody-negative-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology